Open AccessGold nanosupplement in selective inhibition of methylglyoxal and key enzymes linked to diabetes
Author(s) -
Sengani Manimegalai,
Rajeswari Devi
Publication year - 2017
Publication title -
iet nanobiotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.366
H-Index - 38
eISSN - 1751-875X
pISSN - 1751-8741
DOI - 10.1049/iet-nbt.2017.0032
Subject(s) - methylglyoxal , glycation , enzyme , chemistry , biochemistry , diabetes mellitus , metformin , macromolecule , polyphenol , pharmacology , endocrinology , medicine , antioxidant , receptor
The non‐enzymatic glycation of macromolecules resulting into advanced glycation end products (AGEs) that constituents lead secondary complication in diabetes. Currently, scientists are focusing on identifying a novel compound that possibly inhibits AGEs without affecting normal cellular function. So far a number of natural and synthetic compounds were reported. This study intended to evaluate the gold nanoparticles (GNPs) on carbohydrate digestive enzymes inhibition and methylglyoxal (MGO) trapping ability. Initially, GNPs were synthesised using Couroupita guianensis and characterised. Further, remarkable inhibition of α‐amylase, and glucosidase was found through calorimetric techniques. In addition, the results concluded that GNPs limited the glucose uptake and lead to AGEs inhibition. Also, the mechanistic link behind this study illustrated as MGO inhibition will restrict further glycation of macromolecules, eventually control the complication progression. Collectively, GNPs have significant inhibition of digestive enzymes, MGO and AGEs on dose‐dependent manner and metal coated polyphenols have an ideal therapeutic role in controlling diabetes and its complications.